Access information to support formulary decisions
FormularyDecisions is a secure online platform that facilitates the exchange of information between healthcare decision-makers and life sciences companies to provide healthcare decision-makers with the evidence, resources, and tools to support the product evaluation process.
Acquire product information early
Enhance the way you gather product data via a single, secure platform, available to you, 24/7. There are over 3,000 FDA-approved and pipeline products on the platform. Gain compliant access to the most critical information when considering formulary decisions. In addition, there are over 1 million evidence links to leading scientific resources including the FDA, CDC, NIH, JAMA, PubMed, and more—offering you a more efficient method to source information in support of your product needs.
Understand the US biosimilar market and laws governing every state
Gain centralized access to all pertinent biosimilar information in the US through the Biosimilars Resource Hub. The hub provides FDA guidance on biosimilars, manufacturer resources, and serves as an exclusive repository for substitution laws for all 50 states.
Connect with manufacturers
More than 500 manufacturers (pharma, biotech, medical device) are featured on the platform providing information that includes disease and therapeutic information, abstracts, posters, monographs, and pivotal clinical studies. eDossiers allow users to automatically access manufacturer product information once it becomes available to support the product review process.
White paper
Are US payers getting to grips with cost-effectiveness analysis?
Cost-effectiveness analysis (CEA) is widely used in many countries as part of the broader approach to the health technology assessment (HTA) decision process. It’s common in countries with a national or asocial health insurance system where there is a single payer making decisions for the larger population. In the US, with the multi-payer system, the process is more complex and interpretation expertise of CEAs may vary, making CEA utilization among payers limited.
Xcenda’s FormularyDecision team conducted a study to assess the current use of CEAs by US decision-makers, the challenges that they currently face in using CEAs, and the ways in which these could resolved.